Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032292 · ClinicalTrials.gov registry record · Phase 1
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
A Phase 1 study of Graft Vs Host Disease, sponsored by Facet Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 7
- Study locations
NCT00032292 is a Phase 1 study of Graft Vs Host Disease that has completed, run by Facet Biotech. The registered enrollment target is 34 participants, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (75% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT00032292, a Phase 1 study of Graft Vs Host Disease, has completed, sponsored by Facet Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an investigational monoclonal antibody administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). Patients will be eligible for enrollment within 24 hours of beginning standard steroid treatment. The research is being conducted at up to 10 clinical research sites in the US.
Conditions Studied
Interventions
- DRUG Visilizumab
Study Locations (7)
California
- City of Hope National Medical Center - Duarte
- Stanford University Medical Center - Stanford
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- Duke University - Durham
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2002-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032292
The ClinicalTrials.gov registry entry for NCT00032292 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (75% lower). The listed sponsor is Facet Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Visilizumab is the first listed.
NCT00032292 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Missouri, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00032292 about?
NCT00032292 is a clinical study titled "Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease". The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an investigational monoclonal antibody administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). Patients will be eligible for enrollment within 24 hours of begi...
What is the current status of trial NCT00032292?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2002-03. Estimated completion is 2006-08.
What conditions does trial NCT00032292 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
What interventions are being tested in trial NCT00032292?
The interventions under investigation include: Visilizumab (DRUG).
Who is sponsoring clinical trial NCT00032292?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00032292 being conducted?
This trial has 7 study locations across California, Missouri, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
COMPLETED · Phase 1
-
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.